Travere Presents New Biomarker Data at ASN Kidney Week Suggesting FILSPARI® (sparsentan) May Modify Underlying Disease Pathophysiology in IgA NephropathyBusiness Wire · 1 day ago
Earnings Preview: Travere Therapeutics (TVTX) Q3 Earnings Expected to DeclineZacks Investment Research · 2 days ago
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire · Oct 12, 2026
Travere to Present New Data Supporting FILSPARI® (sparsentan) as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026Business Wire · Oct 2, 2026
Kuehn Law Encourages Investors of Travere Therapeutics, Inc. to Contact Law FirmPRNewsWire · Sep 30, 2026
Travere Therapeutics (NASDAQ:TVTX) Shares Gap Down – Time to Sell?Defense World · Sep 24, 2026Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II). Sparsentan received accelerated FDA approval in February 2023 and full approval in September 2024 to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 4, 2026 | -$0.13 | -$0.37 | Miss |
| May 4, 2026 | -$0.30 | -$0.39 | Miss |
| Feb 19, 2026 | $0.03 | $0.03 | Beat |
| Oct 30, 2025 | -$0.31 | $0.28 | Beat |
| Aug 6, 2025 | -$0.28 | -$0.14 | Beat |
| May 1, 2025 | -$0.55 | -$0.47 | Beat |